Otros idiomas Adagene Inc.

Acciones

ADAG

US0053291078

Diferido Nasdaq Otros sitios de cotización 19:25:40 02/05/2024			Varia. Cinco días.	Varia. 1 de enero.
2,41 ^USD	+3,43 %		+2,55 %	+24,77 %

29/03	Adagene Inc. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023	CI
29/03	Adagene Inc. anuncia cambios en el Consejo de Administración	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Adagene : Entry into Sales Agreement - Form 6-K	29/03
Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update	29/03
Adagene Inc. Announces Board Changes	29/03
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board	07/03
Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board	07/03
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024	27/02
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024	27/02
ADRs Close Higher, Ambow Education Holding Ltd. Climbs 117.4%	16/02
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	09/02
Adagene Gets China Clearance to Assess Colorectal Cancer Treatment Combination	09/02
Adagene Inc. Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody	09/02
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)	09/02
ADRs End Higher; The9 Climbs 16%	19/01
Adagene Reports Positive Data on Colorectal Cancer Treatment Combination	17/01
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)	16/01
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)	16/01
Adagene Inc. Announces Data from its Presentation at the American Society of Clinical Oncology 2024 Gastrointestinal (GI) Cancers Symposium	16/01
ADRs End Lower; Aslan Pharmaceuticals Declines 38%	16/01
ADRs Slump, Grifols S.A. Declines 14.0%	11/01

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Adagene Inc.

Acciones

ADAG

US0053291078

Otros idiomas

Filtros